Xilio Therapeutics (XLO) Institutional Ownership $0.86 +0.03 (+3.59%) As of 11:39 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Xilio Therapeutics (NASDAQ:XLO)CurrentInstitutional OwnershipPercentage54.29%Number ofInstitutional Buyers(last 12 months)11TotalInstitutional Inflows(last 12 months)$10.93MNumber ofInstitutional Sellers(last 12 months)0 Get XLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data XLO Institutional Buying and Selling by Quarter Xilio Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/16/2025 ADAR1 Capital Management LLC40,000$29K0.0%N/A0.077% 4/29/2025 Avantax Planning Partners Inc.150,399$109K0.0%N/A0.290% 2/17/2025 Trustees of Columbia University in the City of New York249,635$238K0.0%N/A0.568% 2/17/2025 Balyasny Asset Management L.P.343,230$328K0.0%+26.0%0.781% 2/17/2025 Aptus Capital Advisors LLC41,000$39K0.0%N/A0.093% 2/14/2025 Gilead Sciences Inc.9,105,451$8.70M0.6%N/A20.713% 2/13/2025 Raymond James Financial Inc.50,086$48K0.0%N/A0.114% 2/13/2025 Renaissance Technologies LLC296,617$283K0.0%+11.4%0.675% 2/12/2025 Geode Capital Management LLC358,422$342K0.0%+6.0%0.815% 2/12/2025 Takeda Pharmaceutical Co. Ltd.1,475,121$1.42M5.3%N/A3.356% Get the Latest News and Ratings for XLO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Xilio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/6/2025 Raymond James Financial Inc.50,086$48K0.0%N/A0.114% 11/16/2024 Geode Capital Management LLC338,192$266K0.0%+85.0%0.769% 8/12/2024 XTX Topco Ltd33,289$32K0.0%N/A0.076% 8/9/2024 Renaissance Technologies LLC295,000$280K0.0%+18.3%0.799% 5/6/2024 Atlas Venture Life Science Advisors LLC992,912$1.07M0.1%-64.0%2.690% 4/22/2024 PFG Investments LLC30,000$32K0.0%N/A0.087% 2/15/2024 Octagon Capital Advisors LP1,785,000$982K0.2%-23.0%6.481% 11/14/2022Ergoteles LLC12,941$38K0.0%-26.3%0.047% 8/15/2022 Laurion Capital Management LP142,900$417K0.0%N/A0.520% 7/27/2022 Bailard Inc.36,632$107K0.0%N/A0.133% 5/16/2022 Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567% 5/12/2022 Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594% 2/15/2022 Davidson Kempner Capital Management LP29,000$458K0.0%N/A0.109% 2/14/2022 Deerfield Management Company L.P. Series C2,154,061$33.74M0.7%N/A8.078% 2/14/2022 Ghisallo Capital Management LLC30,000$480K0.0%N/A0.113% 2/14/2022 Soleus Capital Management L.P.477,495$7.64M0.8%N/A1.791% 2/11/2022Granite Point Capital Management L.P.10,000$160K0.0%N/A0.038% 2/9/2022 AJU IB Investment Co. Ltd.667,742$10.68M14.9%N/A2.504% 2/8/2022 Northern Trust Corp63,034$1.01M0.0%N/A0.236% 2/7/2022 Monashee Investment Management LLC214,253$3.43M0.8%N/A0.803% 2/7/2022RiverVest Venture Management LLC1,441,444$23.06M16.5%N/A5.406% 2/2/2022 New York State Common Retirement Fund5,568$89K0.0%N/A0.021% (Data available from 1/1/2016 forward) XLO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of XLO shares? During the previous two years, 14 institutional investors and hedge funds held shares of Xilio Therapeutics. The most heavily invested institutionals were Gilead Sciences Inc. ($8.70M), Takeda Pharmaceutical Co. Ltd. ($1.42M), Atlas Venture Life Science Advisors LLC ($1.07M), Octagon Capital Advisors LP ($982K), Geode Capital Management LLC ($342K), Balyasny Asset Management L.P. ($328K), and Renaissance Technologies LLC ($283K).Learn more on XLO's institutional investors. What percentage of Xilio Therapeutics stock is owned by institutional investors? 54.29% of Xilio Therapeutics stock is owned by institutional investors. Learn more on XLO's institutional investor holdings. Which institutional investors have been buying Xilio Therapeutics stock? Of the 12 institutional investors that purchased Xilio Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Gilead Sciences Inc. ($9.11M), Takeda Pharmaceutical Co. Ltd. ($1.48M), Trustees of Columbia University in the City of New York ($249.64K), Geode Capital Management LLC ($175.57K), Avantax Planning Partners Inc. ($150.40K), Raymond James Financial Inc. ($100.17K), and Renaissance Technologies LLC ($75.87K). How much institutional buying is happening at Xilio Therapeutics? Institutional investors have bought a total of 11,547,249 shares in the last 24 months. This purchase volume represents approximately $10.96M in transactions. Which Xilio Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Xilio Therapeutics stock in the last 24 months: Atlas Venture Life Science Advisors LLC ($1.77M), and Octagon Capital Advisors LP ($533.50K). How much institutional selling is happening at Xilio Therapeutics? Institutional investors have sold a total of 2,299,932 shares in the last 24 months. This volume of shares sold represents approximately $2.20M in transactions. Related Companies PBYI Institutional Ownership KRRO Institutional Ownership LFVN Institutional Ownership SLS Institutional Ownership FTLF Institutional Ownership NKTX Institutional Ownership CYBN Institutional Ownership TNGX Institutional Ownership EPRX Institutional Ownership ACRS Institutional Ownership This page (NASDAQ:XLO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XLO Stock Free XLO Stock Alerts